Toward a new frontier in myocardial reperfusion therapy: emerging platelet preeminence.
about
Debate: When should we intervene in unstable angina - Time for an old look?Results from clinical trials on ST-elevation myocardial infarction in a historic perspective with some pathophysiological aspectsSystematic review of antiplatelet therapy for the prevention of myocardial infarction, stroke or vascular death in patients with peripheral vascular diseaseGlycoprotein receptor inhibitors in the management of acute coronary syndromesGlycoprotein IIb/IIIa antagonism and fibrinolytic therapy for acute myocardial infarctionThe role of aspirin resistance in the treatment of acute coronary syndromesCardiopulmonary bypass in patients with pre-existing coagulopathyEmerging anticoagulant and thrombolytic drugs.The therapeutic use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes.Use of glycoprotein IIb/IIIa inhibitors in unstable angina and non-ST-elevation myocardial infarction.Safety evaluation of tirofiban.Efficacy and safety of eptifibatide versus tirofiban in acute coronary syndrome patients: A systematic review and meta-analysis.New plasminogen activators: a clinical review.Update in internal medicine.Providing full recovery with single-dose intravenous reteplase in a patient presented to emergency department with acute ischemic stroke.Coagulation factor Xa: the prothrombinase complex as an emerging therapeutic target for small molecule inhibitors.Thrombolytic drugs in acute myocardial infarction.Platelet glycoprotein IIb/IIIa receptor antagonists and their use in elderly patients.Glycoprotein IIb/IIIa antagonists in the setting of rescue percutaneous coronary intervention.Optimizing glycoprotein IIb/IIIa inhibition: lessons from recent randomized controlled trials.Facilitated thrombolysis: dethrombosis?Glicoprotein (GP) IIb/IIIa inhibitors for acute stroke treatment.Design and prediction of new anticoagulants as a selective Factor IXa inhibitor via three-dimensional quantitative structure-property relationships of amidinobenzothiophene derivatives.Pharmacological antithrombotic adjuncts to percutaneous coronary intervention.Antiplatelet drug 'resistance'. Part 1: mechanisms and clinical measurements.Use of clopidogrel in the reduction of myocardial damage during percutaneous coronary intervention.Triple antiplatelet therapy in acute coronary syndromes.New advances in the management of acute coronary syndromesGlycoprotein IIb/IIIa inhibitors and acute coronary syndromes: summary report of the full submission to NICE, and beyond.Increase of myocardial salvage and left ventricular function recovery with intracoronary abciximab downstream of the coronary occlusion in patients with acute myocardial infarction treated with primary coronary intervention.Antithrombotic agents in the treatment of severe sepsis.Elevated levels of interleukin-1?-converting enzyme and caspase-cleaved cytokeratin-18 in acute myocardial infarctionComparison of ReoPro® (abciximab) versus intracoronary thrombolysis for early coronary stent thrombosis
P2860
Q24792342-28620340-886D-45BA-B0CB-54E0D8D5DCF5Q28166431-937E0F19-0EF3-4067-BA8A-9324C0490503Q28185314-69709D02-0411-44A7-9619-0A9F23E9BF2BQ28193156-C73D9C77-0C6C-487E-91DE-97F654E49BAFQ28193195-29A3BD83-42C5-4D5E-9D06-4B5835C60AECQ28221026-F864AF2F-CD95-4F54-A168-A48A0B3E93B1Q33365668-19C8B144-E8A7-42B0-8D2A-5426E17CFDC6Q33367019-50EDC30B-89C0-4E1F-ADE0-FE0EA9CE8FD1Q33367036-5F621B1A-D491-4F27-8F8B-8C382E78D220Q33369310-7EB17219-C0D2-4E47-A3FB-7D5159C6390BQ33391065-C1445B87-93EB-4F45-B898-A233685C786AQ33441432-B8D9822E-C2D9-42CD-983D-8EDD5A8438D8Q33542948-C665801A-111E-4902-A5CB-3A60DE62CEC0Q33588350-07B93362-FA39-4AE1-845A-AB9C38657BB6Q33626119-AA8EF93D-01B1-4EF7-91B8-50675DAF0E5FQ33751572-927AF6EF-B006-4825-B9AA-F128167A0421Q33868351-B0C99A48-8863-4BD8-84F6-319152E97213Q33914229-A26E8749-D923-4101-B5A2-87CD779E160AQ34684097-00AD5947-3300-4D46-8236-F2BD7C47C83CQ34712338-FC77D88C-5DAA-4692-AFF6-7A7137B078BAQ34743945-3C7A120A-1D10-4B1C-B50A-7ED82BCD314EQ35008537-D52BF443-14A4-4064-99E2-8969D479839DQ35223237-08A578AF-34A0-4D6D-A96D-1DA6D0BF63FFQ36787291-BCCA1D2C-73C7-434D-9BF6-79DAC4C7732DQ37437158-B3F44477-23AF-43CD-9305-ACCAAFBD2D57Q37479082-37E6135F-0764-4320-8C72-CC41D151A21FQ37929162-0C8F2E4F-A4AB-45AA-8263-F1DDFE601AEEQ39431752-015B67E5-435E-43C2-A413-E3786776F573Q42139077-0100EE64-928A-480B-A4FC-8C492982925EQ44916106-1CA78235-8605-4F1F-AE11-A093E82F33DDQ46576624-3F50AB13-659E-4D5B-89C7-55DF363A0FEAQ57305797-0552DED4-657D-4902-A5E4-5EB1ED486955Q58292254-77AF4CBB-41A7-4FD2-A1F8-231CEAFC7830
P2860
Toward a new frontier in myocardial reperfusion therapy: emerging platelet preeminence.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
1998年论文
@zh
1998年论文
@zh-cn
name
Toward a new frontier in myocardial reperfusion therapy: emerging platelet preeminence.
@en
type
label
Toward a new frontier in myocardial reperfusion therapy: emerging platelet preeminence.
@en
prefLabel
Toward a new frontier in myocardial reperfusion therapy: emerging platelet preeminence.
@en
P356
P1433
P1476
Toward a new frontier in myocardial reperfusion therapy: emerging platelet preeminence.
@en
P304
P356
10.1161/01.CIR.97.2.211
P407
P50
P577
1998-01-01T00:00:00Z